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Abstract: Cerebral cavernous malformations (CCMs) are vascular malformations that can be the result 
of the deficiency of one of the CCM genes. Their only present treatment is surgical removal, which is not 
always possible, and an alternative pharmacological strategy to eliminate them is actively sought. We 
have studied the effect of the lack of one of the CCM genes, CCM3, in endothelial and non-endothelial 
cells. By comparing protein expression in control and CCM3-silenced cells, we found that the levels of 
the Epidermal Growth Factor Receptor (EGFR) are higher in CCM3-deficient cells, which adds to the 
known upregulation of Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) in these cells. 
Whereas VEGFR2 is upregulated at the mRNA level, EGFR has a prolonged half-life. Inhibition of EGFR 
family members in CCM3-deficient cells does not revert the known cellular effects of lack of CCM 
genes, but it induces significantly more apoptosis in CCM3-deficient cells than in control cells. We 
propose that the susceptibility to tyrosine kinase inhibitors of CCM3-deficient cells can be harnessed to 
kill the abnormal cells of these lesions and thus treat CCMs pharmacologically. 
Keywords: cavernoma; CCM3; PDCD10; EGFR; VEGFR2; ErbB2; Lapatinib 
 
1. Introduction 
Cerebral cavernous malformations (CCMs, OMIM#116860) are vascular malformations with a 
high prevalence of 1 in 200–250 individuals. They develop in the venous-capillary vascular bed 
almost exclusively in the central nervous system, and it is because of this location that they give rise to 
clinically relevant symptoms, from headaches to seizures and bleeding [1–3]. CCMs are low-flow 
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vascular malformations with thrombosis and calcifications as typical features, and their endothelium 
has altered cell-to-cell junctions, which causes leakiness [4]. These abnormal endothelial features have 
lent support to the idea that CCMs arise from an abnormal endothelial behavior, which has been 
confirmed by recent studies [3]. 
Both sporadic and familial forms of CCMs have been described. Familial CCM (fCCM) is 
characterized by the presence of multiple lesions and an autosomal dominant inheritance with very 
high penetrability. There have been three CCM genes identified: CCM1 (KRIT1), CCM2 (MGC4607, 
OSM, Malcavernin), and CCM3 (PDCD10, TFAR15) [5–7]. Mutations in these genes are inherited in 
heterozygosis, and cavernomas are formed when they are completely inactivated in an endothelial cell 
because of loss of the non-mutated allele [8–10]. CCM genes codify for adaptor proteins [11]. Study of 
the consequences of the loss of CCM genes in endothelial cells in recent years have shed light on the 
pathogenic mechanisms of CCMs and have even given rise to proposed pharmacological treatments for 
these malformations (see below). However, we still do not fully understand the behavior of a CCM cell 
and thus, how a cavernoma develops and especially how it could be limited or, ideally, deleted. 
CCM gene products play roles in many important general cellular functions, such as 
proliferation and death; adhesion, permeability, cytoskeletal regulation and polarity, ROS 
homeostasis, transmembrane signaling, membrane handling, organelle homeostasis and secretion, 
kinase and gene regulation (most importantly the Mitogen-activated protein kinase kinase kinase 3 
(MEKK3)/Mitogen-activated protein kinase kinase 5 (MEK5)/ Extracellular signal-regulated protein 
kinase 5 (ERK5)/Myocyte-specific enhancer factor 2C (MEF2C)/ Kruppel Like Factor 2 and 4 (2–4) axis), 
and differentiation (for reviews in recent years see [3,12–15]). Some of these effects have been related 
to the endothelial phenotype of CCMs, and have inspired therapeutic approaches, several of which 
are active in preventing lesion development in animal models. The anti-inflammatory drug sulindac 
inhibits the enhanced β-catenin activity of CCM3-deficient endothelial cells and reduces lesion 
development in a mouse model of CCM3 deficiency [16]. The Rock inhibitor Fasudil precludes the 
development of lesions in a chronic model of cavernoma development [17]. 3TSR, an antiangiogenic 
fragment of the thrombospondin-1, suppresses the development of cavernomas in a CCM1-deficient 
mouse model [18]. The MEKK3 inhibitor ponatinib can prevent the formation of CCM lesions and 
reduce the growth of lesions in animal models of cavernoma development [19]. Furthermore, 
indirubin 3 monoxime, a drug derived from Chinese traditional medicine, alleviates CCM burden in 
mice [20]. However, to the best of our knowledge none of these treatments has been shown to kill 
cells deficient of CCM genes, and this would be very useful for people who are diagnosed when 
lesions are already there. 
We show in this article that CCM3 deficiency results in high expression of the Epidermal Growth 
Factor Receptor (EGFR) and an enhanced susceptibility to inhibition of the EGFR family of proteins. 
This may give rise to new therapeutic strategies. The strategy we propose would actively kill the 
abnormal cells in cavernoma lesions. Although animal experiments will be needed to discard possible 
deleterious effects, it would effectively delete lesions already formed. 
2. Experimental Section 
2.1. Cell Culture 
Human umbilical vein endothelial cells (HuVECs) were isolated as previously described [21] 
from umbilical cords obtained from the University Clinical Hospital of Santiago de Compostela 
where written informed consent was obtained. The procedure was approved by the Hospital ethics 
committee (Comité de ética da Investigación de Santiago-Lugo, Galicia, Spain), ref 2014/493. HUVECs 
were routinely grown in VascuLife EnGS Endothelial Cell Culture Medium (LifeLine Cell 
Technology, Oceanside, CA, USA #LL-0002) supplemented with VascuLife® EnGS LifeFactors® Kit 
(LifeLine Cell Technology, Oceanside, CA, USA #LS-1019) and 100 units/mL penicillin and 100 µg/mL 
streptomycin (Gibco Thermo Fisher Scientific, Waltham, MA, USA #15140163). HUVEC between P2 
and P4 were used for all experiments. 
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The A549 human lung adenocarcinoma cell line was obtained from the European Collection of 
Authenticated Cell Cultures (ECACC, Public Health England, UK). It was maintained in DMEM 
(Dulbecco’s modified Eagle’s medium) (Sigma, St Louis, MO, USA #D6429) supplemented with 10% 
fetal bovine serum (FBS) (Gibco Thermo Fisher Scientific Inc., Waltham, MA, USA #10270-106), 100 
units/mL penicillin and 100 µg/mL streptomycin (Gibco Thermo Fisher Scientific Inc., Waltham, MA, 
USA #15140-163). 
Human Cerebral Microvascular Endothelial Cells (hCMEC/D3) [22] were obtained from Dr 
Pierre-Olivier Courad and cultured as recommended, on 0.1% gelatin (Sigma, St Louis, MO, USA 
#G9391) coated plates in Endothelial Cell Growth Basal Medium-2 (EBM-2, Lonza, Basel 
Switzerland#CC-3156) supplemented with 5% FBS (Gibco Thermo Fisher Scientific Inc., Waltham, MA, 
USA #10270-106), 1.4 μM hydrocortisone (Sigma, St Louis, MO, USA #H2270), 5 μg/mL ascorbic acid 
(Sigma, St Louis, MO, USA #A4403), 1% chemically defined lipid concentrate (Gibco Thermo Fisher 
Scientific Inc., Waltham, MA, USA #11905-031), 10 mM 4-(2-hydroxyethyl-1-piperazineethanesulfonic 
acid (HEPES, Sigma, St Louis, MO, USA #H3375), 1 ng /mL human basic fibroblast growth factor 
(Gibco Thermo Fisher Scientific Inc., Waltham, MA, USA #13256-029) and 100 units/mL penicillin and 
100 µg/mL streptomycin (Gibco Thermo Fisher Scientific Inc., Waltham, MA, USA#15140163). 
hCMEC/D3 cells between P13 and P26 were used for all experiments. 
Cells were transduced with lentiviral particles encoding either of two different human small 
hairpin RNAs (shRNAs) for CCM3 (shCCM3 and shCCM3.4), or non-targeting (shNT). Oligonucleotides 
were inserted in pLKO.1 plasmid and lentiviral particles were obtained by its cotransfection with 
psPAX2 and pMD2.G plasmids in HEK293 cells (oligonucleotides sequences shown in Table S1). All 
cells were selected with Puromycin (Calbiochem, Merck, Darmstadt, Germany #CAS 58-58-2) after 
transduction. 
2.2. Reverse Transcription-Quantitative Polymerase Chain Reaction (RT-qPCR) Analysis 
TRIzol reagent (Life Technologies, Carlsbad, CA, USA, #15596018) was used to extract the total RNA 
from cells, RNA was reverse-transcribed using random hexamers, and the mRNA expression level was 
determined using PowerUp™ SYBR™ Green Master Mix (Thermo Fisher Scientific Inc., Waltham, MA, 
USA #A25778) using a StepOnePlus™ Real-Time PCR System. 
2.3. Antibodies and Drugs 
The antibodies used are listed in Table S3. 
Lapatinib (Selleckchem, TX, USA #S2111), Vatalanib (Selleckchem, TX, USA #S1101), BIX02189 
(Selleckchem, TX, USA #S1531), Chloroquine (Sigma St Louis, MO, USA #C6628), and MG132 (Sigma, 
St Louis, MO, USA #C2211) were dissolved in dimethylsulfoxide (DMSO). Vascular Endothelial 
Growth Factor (VEGF, Sigma, St Louis, MO, USA #V5765) and Epidermal Growth Factor (EGF, 
Calbiochem, Merck, Darmstadt, Germany #PHG0313) were dissolved in water. 
2.4. Proteome Analysis 
Proteome analysis of HuVECs was performed using the Proteome Profiler Human Soluble 
Receptor Array Non-Hematopoietic Panel (R&D Systems, MN, USA #ARY012) following 
manufacturer’s instructions and quantified using the ImageJ software (version 1.52s, National 
Institute of Health, USA). 
2.5. Western Blot 
Cells were solubilized in cold radioimmunoprecipitation assay (RIPA, receipt by request) lysis 
buffer plus protease and phosphatase inhibitors. PVDF membranes were blocked for 1  h with 
TBS/0.1%-Tween buffer containing 5% (w/v) non-fatty milk and incubated with the corresponding 
primary and secondary antibodies, blots were developed using ECL® Chemiluminescent detection 
reagents (Thermo Fisher Scientific Inc., Waltham, MA, USA #32106) and Fuji Medical X-ray Films 
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(Fujifilm, Shangai, Japan). The software ImageJ (version 1.52s, National Institute of Health, USA) was 
used to quantify the Western blot signals. 
2.6. Immunofluorescence 
Cells were grown to confluence on poly-L-lysine-coated coverslips (Sigma, St Louis, MO, USA 
#P4832) and the indicated treatments were performed. Then, cover slips were washed twice with PBS, 
and fixed for 15 min at room temperature with 4% p-formaldehyde in PBS pH 7.4, at dark conditions, 
permeabilized with Triton X-100 0.5%, blocked with 10% FBS for 60 min and incubated with indicated 
primary antibodies overnight at 4 °C, then for 1 h at room temperature with Alexa Fluor® 546 
conjugated secondary antibodies, and stained with DAPI. Slides were observed in a confocal 
microscope (Leica Microsystems, Mannheim, Germany) using a HCX PL APO CS 63x objective. 
Images were captured and analyzed using the Leica LAS AF software (version 3.7.0.20979, Leica 
Microsystems, Wetzlar, Germany). 
2.7. Flow Cytometry 
A549 cells were grown to confluence. Then, cells were harvested and fixed for 15 min at room 
temperature with 4% p-formaldehyde in PBS pH 7.4 in the dark, and incubated with antibody against 
EGFR (clone EGFR1, #ab30, Abcam, Cambridge, UK) for 1 h at room temperature and for 30 min at 
room temperature with Alexa Fluor® 488 conjugated secondary antibody, both antibodies in 1% BSA 
solution. Cells (104 per sample) were acquired in a BD Accuri C6 (Becton Dickinson, Oxford, UK) flow 
cytometer. Cells were acquired and gated by FSC and SSC and analyzed with FlowJo™ software 
(version 10.1, FlowJo LLC, Ashland, OR, USA). 
2.8. Fluorescence Detection of Caspase 3/7 Activation 
hCMEC/D3 or HuVEC cells were seeded at 9 × 104 cells/well in 24-well plates. The following 
day, 2 µM Lapatinib was added alongside with 8 µM of CellEvent™ Caspase-3/7 Green Detection 
Reagent (Invitrogen™, Thermo Fisher Scientific Inc., Waltham, MA, USA #C10423). Cells were imaged 
by fluorescence at the indicated times after treatment. Apoptotic cells were counted using the ImageJ 
software (version 1.52s, National Institute of Health, USA). 
2.9. Statistics 
Statistical analysis was performed using GraphPad software (https://www.graphpad.com/), 
(version 7.0, San Diego, CA, USA) applying the Mann–Whitney test when two groups were compared 
and ANOVA analysis with a Bonferroni post hoc correction when comparing more than two groups. 
A value of p < 0.05 was considered significant. All graphs represent the mean ± SEM. 
3. Results 
To try to identify differences induced by CCM3 deficiency at the protein level, we generated 
CCM3-deficient HuVECs. CCM3 downregulation using shCCM3 shRNA was efficient at the mRNA 
(Figure 1a) and protein level (Figure 1b). We then compared the levels of membrane proteins in HuVECs 
transduced with shNT and shCCM3-expressing lentivirus by using a proteome profiler array. The only 
protein that had a double intensity on shCCM3 cells was EGFR, whereas several beta-integrins were 
close to that difference (Figure 1c,d). We were intrigued by the differences in EGFR, as it is a druggable 
protein with well-developed inhibitors. Furthermore, the levels of the major tyrosine kinase receptor in 
endothelial cells, VEGFR2, have been proposed to be affected by CCM deletion [23–25], but to our 
knowledge nothing has been seen regarding the EGF receptor. 
We next looked at the levels of EGFR by Western blot. In accordance to the results of the proteome 
assay, EGFR was upregulated in CCM3-deficient HuVECs (Figure 1d). Importantly, when we 
downregulated CCM3 by lentiviral delivery of shRNA in the immortal endothelial cell line hCMEC/D3, 
a model of blood brain barrier (Figure 2a,b), EGFR was also upregulated (Figure 2c), showing that this 
effect is not restricted to a particular type of endothelial cell. 
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To see if the effect of CCM3 on EGFR family proteins could be seen also in cells of non-endothelial 
origin, we inhibited CCM3 in A549 human adenocarcinoma cells by lentiviral transduction of two 
different shRNAs. Inhibition of CCM3 was efficient in these cells, both at mRNA (Figure 2d), and 
protein (Figure 2e) levels with both shRNAs. Interestingly, transduction with shCCM3 showed at 
least some of the same effects that have been already shown in endothelial cells [3], as seen by 
hyperphosphorylation of ERK5 (Figure 2f), and stimulation of KLF2 expression (Figure 2g). EGFR 
was overexpressed in A549 cells transduced with both shCCM3 and shCCM3.4 shRNAs (Figure 2h), 
suggesting that the role of CCM3 on EGFR regulation is general and not restricted to one cell type. 
As stated above, CCM deficiency affects the levels and function of VEGFR2, the major tyrosine 
kinase receptor in endothelial cells. We measured VEGFR2 levels in HuVECs transduced with shNT 
or shCCM3 RNAs. VEGFR2 was upregulated when CCM3 was inhibited, both in the absence and in 
the presence of VEGF (Figure 3a), although it had not shown up in the array. The same was true for 
hCMEC/D3 cells (Figure 3b). To explore the mechanisms of upregulation of the different proteins, we 
measured the mRNAs of VEGFR2 and EGFR in HuVECs (Figure 3c). Surprisingly, while the levels of 
VEGFR2 mRNA were clearly induced by lack of CCM3, EGFR mRNA was unaffected, suggesting that 
the effect of CCM3 on the levels of this protein was posttranslational. The mRNA levels of EGFR were 
also not induced in A549 cells (Figure 3d). To see if CCM3 affected the stability of EGFR, we looked at 
its levels in A549 cells treated with the protein synthesis inhibitor cycloheximide. EGFR half-life was 
prolonged in cells lacking CCM3 (Figure 3e). Moreover, chloroquine treatment resulted in higher 
levels of EGFR in both shNT and shCCM3 cells (Figure 3f), whereas treatment with the proteasome 
inhibitor MG132 did not (Figure 3g), suggesting that lysosomal degradation is the main route of 
EGFR degradation in these cells and that lack of CCM3 impairs it. 
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Figure 1. Analysis of membrane proteins in CCM3-deficient human umbilical vein endothelial cells 
(HUVECs); (a) CCM3 mRNA levels in HuVECs transduced with shNT and shCCM3 shRNAs. * p < 
0.001; (b) CCM3 protein levels in the same cells; (c) Differences levels of membrane proteins between 
shNT and shCCM3 HuVECs as seen in a proteome profiler array; (d) List of proteins in the proteome 
profiler assay, with the log2 of their difference between shCCM3 and shNT cells. EGFR shown in red. 
(e) Western blot of Epidermal Growth Factor Receptor (EGFR) HuVECs transduced with shNT and 
shCCM3 shRNAs. Right panel: quantification of EGFR Western blots. * p < 0.05. 
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Figure 2. Receptors of the EGFR family are upregulated in several CCM3-deficient cells; (a) mRNA 
levels, and (b) Protein levels, of CCM3 in in hCMEC/D3 endothelial cells transduced with shNT and 
shCCM3 shRNAs. * p < 0.001; (c) Western blot of EGFR in hCMEC/D3 cells transduced as in (a). Right 
panel: quantification of EGFR Western blots. * p < 0.05; (d) mRNA levels; and (e) Protein levels, of 
CCM3 in A549 cells transduced with shNT, shCCM3, or shCCM3.4 shRNAs; (f) Western blot of ERK5 in 
A549 cells transduced with shNT or shCCM3 shRNAs; (g) mRNA levels of KLF2 in cells transduced as 
in (f); (h) Western blot of EGFR in A549 cells transduced with shNT, shCCM3 or shCCM3.4 shRNAs. 
Right panel: quantification of EGFR Western blots. * p < 0.05. 
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Figure 3. Upregulation of EGF family receptors in CCM3-deficient cells is postranscriptional; (a) VEGFR2 
and phosphorylated VEGFR2 (pY1175) in shNT and shCCM3 HuVECs before and after VEGF 
stimulation; (b) Western blot of VEGFR2 in hCMEC/D3 cells; (c) mRNA levels of EGFR andVEGFR2 in 
HuVECs. * p < 0.05; (d) mRNA levels of EGFR in A549 cells; (e) EGFR in A549 cells transduced with 
shNT and shCCM3 shRNAs before and after treatment with the protein synthesis inhibitor 
cycloheximide. (f) EGFR Western blot in shNT and shCCM3 A549 cells treated or not with 
chloroquine. (g) Same as in (f) in cells treated or not with the proteasome inhibitor MG132. 
Lysosomal degradation of EGFR is a possible result of EGFR endocytosis after EGF stimulation, and 
CCM3 plays a role in endo and exocytosis [26–28]. To see if the difference in EGF receptor stability 
depended on EGF treatment, we serum-deprived cells and treated them with EGF to induce EGFR 
endocytosis and degradation. Both in hCMEC/D3 (Figure 4a), and A549 cells (Figure 5) EGFR levels 
were higher in shCCM3 cells even before EGF addition, suggesting that the effect of CCM3 on EGFR 
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stability was not dependent on EGF. Moreover, we have not detected any defective endocytosis of 
EGFR in shCCM3 cells. EGFR is mainly in the plasma membrane in untreated cells, and is redistributed 
to intracellular vesicles after EGFR addition, independently of CCM3 status, as seen by 
immunofluorescence (Figure 4b). Furthermore, when the EGFR in the plasma membrane of serum-
deprived cells was measured by flow cytometry, CCM3-deficient cells did not show a higher intensity 
than control cells (Figure 4c). We concluded that CCM3 did not affect EGFR endocytosis, before or 
after EGF addition. 
 
Figure 4. EGFR endocytosis is not inhibited in CCM3-deficient cells. (a) hCMEC/D3 endothelial cells 
transduced with shNT and shCCM3 shRNAs were serum deprived and treated with 100 ng/mL EGF 
for the indicated times, and EGFR levels were analyzed by Western blot; (b) A549 cells transduced 
with shNT and shCCM3 shRNAs were serum deprived and then treated or not with EGF 100 ng/mL 
previously. Then, cells were stained for immunofluorescence analysis of EGFR (red) expression and 
distribution. Images were captured at 63× and merged with DAPI (blue). (c) A549 cells transduced 
with shNT and shCCM3 shRNAs were serum deprived and the EGFR in their plasma membrane 
measured by flow cytometry. 
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Figure 5. High levels of EGFR in CCM3-deficient cells results in enhanced phosphorylation of ERK1/2 
after EGF treatment. A549 cells transduced with shNT and shCCM3 shRNAs were serum deprived 
and treated with 100 ng/mL EGF for the indicated times. EGFR, ERK5, ERK1/2 and pERK1/2 were 
analyzed by Western blot. 
Because EGFR is a druggable protein with well-characterized inhibitors, our next step was to see 
whether its higher levels in CCM3-deficient cells had a functional significance. One of the best 
characterized responses to EGFR stimulation by EGF is phosphorylation of Extracellular signal-
regulated protein kinases 1 and 2 (ERK1/2), which we analyzed in endothelial cells untreated or treated 
with EGF for different times. Cells deficient for CCM3 had more phosphorylation of ERK1/2, in EGF-
treated cells, which accompanied the expected effect on ERK5 phosphorylation, which also 
responded to EGF, as described [29] (Figure 5). 
It is well established that CCM deficiency results in overactivation of the MEKK5/MEK3/ERK5 
axis, and a resulting overexpression of the KLF2 and KLF4 transcription factors. To see if EGFR family 
members played a role in this deregulation in CCM3-deficient cells, we treated cells with Lapatinib, 
an inhibitor of the kinase activity of EGFR family proteins [30]. Lapatinib inhibited both EGFR and 
ERK1/2 phosphorylation in normal and CCM3-deficient A549 cells (Figure 6a). Despite this clear 
biochemical effect, Lapatinib did not consistently inhibit KLF2 or KLF4 overexpression in CCM3-
deficient cells, showing at best a partial effect (Figure 6b). This was also true in endothelial cells, in 
which neither Lapatinib nor the VEGFR2-specific inhibitor vatalanib or the combination of both could 
revert the overexpression of KLF2 or KLF4 in shCCM3 cells (Figure 6c). Furthermore, the effect of 
CCM3 on the distribution of VE-cadherin was also not affected by treatment with either inhibitor or 
their combination (Figure 6d). We concluded that chemical inhibition of EGFR family members does 
not affect the canonical effect of CCM inhibition in endothelial or non-endothelial cells. 
Cancer cells that overexpress EGFR and/or ErbB2 are susceptible to their inhibition by Lapatinib. In 
fact, the main therapeutic effect of this drug is to induce cell growth arrest and death [31]. We wanted 
to know if Lapatinib could affect cell viability in a CCM3-dependent way. When hCMEC/D3 
endothelial cells were treated with this drug at the clinically relevant dose of 2 µM [32,33], they had a 
higher tendency to enter apoptosis, as measured by incubation with a caspase 3/7 fluorogenic substrate 
(Figure 7a). Likewise, HuVECs depleted of CCM3 showed activated caspase 3/7 after 24 h incubation 
with Lapatinib only if CCM3-deficient (Figure 7b). Thus, we concluded that deficiency of CCM3 
made endothelial cells susceptible to apoptosis by Lapatinib. While this is probably because of their 
overexpression of EGF receptor, formal proof of this would require genetic inhibition of EGFR. 
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Figure 6. Inhibition of EGFR family receptors in CCM3-deficient cells does not affect overexpression 
of KLF transcription factors or VE cadherin distribution; (a) A549 cells transduced with shNT and 
shCCM3 shRNAs were treated or not with the EGFR family inhibitor Lapatinib 10 µM, and Western 
blots performed for the indicated proteins; (b) Difference of KLF2 (left) and KLF4 (right) expression 
in A549 cells transduced with shNT or with shCCM3 shRNAs, treated or not with Lapatinib or the 
MEK5/Erk5 inhibitor BIX02189. * p < 0.05; (c) Difference of KLF2 (left) and KLF4 (right) expression in 
hCMEC/D3 cells transduced with shNT or with shCCM3 shRNAs, treated or not with Lapatinib or 
the VEGFR2 inhibitor Vatalanib; (d) VE cadherin (red) distribution in hCMEC/D3 cells transduced 
with shNT or with shCCM3 shRNAs, treated or not with Lapatinib , BIX02189, or Vatalanib. Images 
are shown merged with DAPI (blue). 
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Figure 7. Deficiency of CCM3 makes endothelial cells more susceptible to inhibition of EGFR family 
receptors; (a) hCMEC/D3 cells transduced with shNT and shCCM3 shRNAs were treated with the 
EGFR family inhibitor Lapatinib for 24 h at 2 µM, apoptotic cells were detected. The number of cells 
with activated caspase 3/7 are represented. # p = 0.07. (b) HuVECs transduced with shNT and shCCM3 
shRNAs were treated with 2 µM of the EGFR family inhibitor Lapatinib for 24 h and apoptotic cells 
were detected using the CellEvent™ Caspase-3/7 Green Detection Reagent (left panel). Number of 
caspase 3/7 positive cells at the indicated times were counted (right panel) * p < 0.05 vs. shNT. 
4. Discussion 
We show in this paper that CCM3 deficiency induces an overexpression of the EGF receptor, 
and a susceptibility of CCM3-deficient cells to inhibition of the EGFR family of receptors.  
Deregulation, usually overactivation, of VEGFR2 is a common alteration in cells deficient of a CCM 
gene. Lack of CCM1 induces VEGF deregulation and thus VEGFR2 activation, without higher levels of 
VEGFR2 protein [18,23], whereas CCM3-deficient cells have been reported to have a destabilized 
VEGFR2 [34], but more consistently to have enhanced VEGFR2 phosphorylation [24] and high 
VEGFR2 protein levels [25], which is in accordance with our results.  
In this article, we show that besides an upregulation of VEGFR2, CCM3-deficient cells have high 
levels of EGFR by a different mechanism: impaired degradation of the protein. Our results point to a 
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defect in lysosomal degradation of the receptors in CCM3-deficient cells, despite which we have seen 
no apparent differences in the endocytosis of EGFR or its colocalization with lysosomal proteins, 
which suggests a specific defect in degradation itself, which affects the basal degradation of the protein, 
rather than its EGF-induced degradation. Alternatively, CCM3-deficient cells may have a defect in EGF 
receptor trafficking in a step different from the endocytic step. Although more experiments will be needed 
to ascertain this, it is intriguing that we and others had previously shown that inhibition of CCMs results 
in impaired autophagy [35,36], an effect that may be related to the one we are reporting here. It also 
agrees with one of the major phenotypic consequences of CCM and specifically of CCM3 deficiency, 
the altered handling of cellular membranes, which has been shown in several different models of CCM3 
deficiency, as in C. elegans [26,37,38], D. melanogaster [39], zebrafish [40], and mammalian cells [27,28].  
The deregulation of EGF receptor has a potentially important consequence: making cells susceptible 
to its inhibition, which could be a viable therapeutic strategy for cavernomas. We explored how this 
alteration on tyrosine kinase receptors relates with one of the main pathways affected by CCM3 loss. 
In our hands, EGF can stimulate ERK5 phosphorylation in serum-deprived cells, which is in accordance 
with previous reports [41]. Furthermore, we see that in early time points after stimulation ERK5 
phosphorylation is higher in shCCM3 cells, an effect that we attribute to their higher receptor levels. 
However, the difference in ERK5 phosphorylation after EGF is transient, and it is lost in the last time 
points after treatment. Moreover, treatment with Lapatinib does not consistently inhibit the 
characteristic KLF2 and KLF4 overexpression of CCM3-deficient cells. 
We also analyzed another potentially useful effect of tyrosine kinase inhibition: the ability to 
differentially affect viability of CCM3-deficient cells. We found that treatment with Lapatinib affects 
the viability of CCM3-deficient cells and not that of control cells. We propose that this differential 
effect is due to EGFR family inhibition, as we have used Lapatinib concentrations that are attained by 
the drug in several tissues in clinically relevant settings [32,33], together with the fact that Lapatinib is 
known to be a very specific inhibitor, targeting exclusively EGF receptor family members at these 
concentrations [30].  
Curiously, similar observations have been made with other kinase inhibitors. Inhibition of VEGFR2 
does not affect the overexpression of KLF2 or KLF4 after CCM2 loss [42], but it can partially prevent the 
development of cavernomas in CCM1-deficient animals [24]. Moreover, many of the drugs that have been 
shown effective in experimental models of CCM deficiency are known to inhibit tyrosine kinase receptors. 
It is the case for Ponatinib, an inhibitor of MEKK3/KLF signaling which prevents formation and 
progression of cerebral cavernous malformations [19]. Additionally, indirubin 3, which was identified as 
a CCM active molecule in a pharmacological screen [20], is known to inhibit both VEGFR2 and EGFR 
among other targets; and the same can be said of sorafenib, a multikinase inhibitor which reduces the 
effects of CCM1 loss in endothelial cells [43]. Thus, there is ample evidence that the use of compounds 
that inhibit receptor tyrosine kinases are a feasible strategy for CCM control. 
Experiments in an animal model of CCM will be needed to know if Lapatinib administration is 
an effective strategy to treat cavernomas. This will also be essential to know if the strategy of killing the 
endothelial cells that form a cavernoma may have drawbacks, the most obvious being the possibility 
of lesion bleeding after endothelial death. Furthermore, most endothelial cells of patients with 
familial cavernomatosis are heterozygous for CCMs, and they may also be more susceptible to 
Lapatinib, a very unlikely possibility, as no haploinsufficient effect has been reported for CCMs to 
date. 
While lesion bleeding would be a serious side effect that would compromise the use of this strategy, 
there are antecedents where endothelial cell death in vascular malformations do not lead to an 
increased risk of bleeding. The beta-blocker propranolol is regularly used to successfully treat 
infantile hemangiomas [44], and its mechanism of action has been shown to involve apoptotic killing of 
the hemangioma endothelial cells [45]. Despite this, no bleeding of these lesions has been described after 
treatment, and propranolol is the treatment of choice for this condition. Furthermore, as it happens with 
propranolol, killing of CCM deficient endothelial cells may not only prevent the development of new 
cavernomas, but also delete those already developed, which would be very useful in many clinical 
settings.  
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